Bristol-Myers Squibb has unveiled the team that will lead its research and development group after its $74 billion acquisition of Celgene is finalized.
Pharmacy
Mylan is expecting shortages of its EpiPen auto-injector to continue, according to an update on the FDA product shortages list.
CVS Health will close some unprofitable stores, according to CNBC.
Insys Therapeutics founder John Kapoor's name will be removed from the University of Buffalo (N.Y.) School of Pharmacy, following Kapoor's conviction last month in a racketeering conspiracy, according to Buffalo News.
Three more states and the District of Columbia filed lawsuits June 3 accusing Purdue Pharma of falsely marketing OxyContin and downplaying the risks of addiction, which fueled the opioid epidemic, according to The Guardian.
Advertisement
The FDA approved Zerbaxa June 3 for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
After success with its pilot sites in Houston, CVS Health plans to open 1,500 HealthHub stores by the end of 2021, the pharmacy retail giant announced June 4.
Becker's Hospital Review has reported the following four drug or biotech company layoffs in the last two weeks. They are listed below, beginning with the most recent.
Heritage Pharmaceuticals, a generic drugmaker in Eatontown, N.J., agreed to pay a settlement on May 31 to resolve allegations of to fix prices for its diabetes drug glyburide, the U.S. Justice Department said.
Disgraced former pharmaceutical company executive Martin Shkreli, currently serving a seven-year prison sentence for defrauding investors, has sued two directors and a former general counsel of Retrophin, the pharmaceutical company he founded, according to CNBC.